ClinicalTrials.Veeva

Menu
P

Palm Research Center | Northwest Location

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
Relamorelin
Olezarsen
LY3298176
Sugar
LY900014
Tirzepatide
K-877
ISIS 678354
IONIS-GHR-LRx

Parent organization

This site is a part of Palm Research Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 71 total trials

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (ONWARDS 11)

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Begins enrollment this month
Diabetes Mellitus, Type 1
Drug: Insulin glargine
Drug: Insulin icodec

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Active, not recruiting
Type 2 Diabetes
Drug: Placebo
Drug: Semaglutide

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling
Type 1 Diabetes Mellitus with Hypoglycemia
Drug: Placebo
Drug: ZT-01, 22 mg

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x...

Enrolling
Acromegaly
Drug: Debio 4126
Drug: Placebo

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling
Hypothyroidism
Drug: Levothyroxine
Drug: Armour Thyroid
Status recently updated

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Not yet enrolling
Enrolling
Hypertension
Cardiovascular Diseases
Drug: Placebo matching Vicadrostat
Drug: Vicadrostat

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 recep...

Active, not recruiting
Obesity
Muscle Loss
Drug: Semaglutide
Drug: Enobosarm

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Drug: Maridebart cafraglutide
Drug: Placebo

The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or...

Enrolling
Overweight
Obesity
Other: Placebo
Drug: Petrelintide

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Active, not recruiting
Type 1 Diabetes Mellitus
Drug: BMF-219

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Active, not recruiting
Obesity
Biological: Nimacimab placebo injection
Biological: Nimacimab injection

Trial sponsors

Lilly logo
Ionis Pharmaceuticals logo
Amgen logo
Boehringer Ingelheim logo
Allergan logo
Dexcom logo
G
I
Novo Nordisk logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems